Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 25.20
- Piotroski Score 3.00
- Grade Outperform
- Symbol (DNTH)
- Company Dianthus Therapeutics, Inc.
- Price $23.64
- Changes Percentage (1.2%)
- Change $0.28
- Day Low $22.92
- Day High $24.06
- Year High $33.77
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $51.50
- High Stock Price Target $52.00
- Low Stock Price Target $51.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.71
- Trailing P/E Ratio -11.77
- Forward P/E Ratio -11.77
- P/E Growth -11.77
- Net Income $-43,555,000
